Losmapimodp38 MAPK inhibitor, orally active CAS# 585543-15-3 |
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Telmisattan
Catalog No.:BCC3863
CAS No.:144701-48-4
- Rosuvastatin Calcium
Catalog No.:BCC3853
CAS No.:147098-20-2
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 585543-15-3 | SDF | Download SDF |
PubChem ID | 11552706 | Appearance | Powder |
Formula | C22H26FN3O2 | M.Wt | 383.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GSK-AHAB; GW856553X; SB856553 | ||
Solubility | DMSO : ≥ 58 mg/mL (151.25 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide | ||
SMILES | CC1=C(C=C(C=C1C2=NC=C(C=C2)C(=O)NCC(C)(C)C)C(=O)NC3CC3)F | ||
Standard InChIKey | KKYABQBFGDZVNQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Losmapimod (GW856553X) is a selective, potent, and orally active inhibitor of p38 MAPK with a pKi values of 8.1 and 7.6 for p38α and p38β, respectively. | |||||
Targets | p38α | p38β | ||||
IC50 | (pKi=8.1) | (pKi=7.6) |
Losmapimod Dilution Calculator
Losmapimod Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6078 mL | 13.0392 mL | 26.0783 mL | 52.1567 mL | 65.1958 mL |
5 mM | 0.5216 mL | 2.6078 mL | 5.2157 mL | 10.4313 mL | 13.0392 mL |
10 mM | 0.2608 mL | 1.3039 mL | 2.6078 mL | 5.2157 mL | 6.5196 mL |
50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.0431 mL | 1.3039 mL |
100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.5216 mL | 0.652 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Losmapimod (GW856553, GW856553X, GSK-AHAB) is a potent and selective inhibitor of p38 MAPK with pKi values of 8.1 and 7.6 for p38α and p38β, respectively [1].
p38 mitogen-activated protein kinase (p38 MAPK) is an intracellular signaling kinase and plays an important role in regulating transcription and translation of the inflammatory response in macrophages and endothelial cells [2].
Losmapimod is an orally active p38 MAPK inhibitor. In the spontaneously hypertensive stroke-prone rats (SHR-SPs) with a salt-fat diet, GSK-AHAB significantly improved survival and renal function in a dose-dependent way and induced vascular relaxation. Also, GSK-AHAB attenuated hypertension, cardiac remodeling, dyslipidemia, plasma renin activity (PRA), interleukin-1 (IL-1) and aldosterone [1]. In patients with hypercholesterolemia, losmapimod improved acetylcholine, sodium nitroprusside and NG-monomethyl-L-arginine (L-NMMA) responses by 25%, 20% and 10%, respectively. Also, losmapimod reduced C-reactive protein (a systemic inflammatory marker) by 57%. These results suggested that losmapimod improved NO-mediated vasodilatation and inhibited inflammation [2]. In patients with chronic obstructive pulmonary disease (COPD), losmapimod (7.5 mg twice daily) reduced plasma fibrinogen by 11% and was well tolerated [3].
References:
[1]. Willette RN, Eybye ME, Olzinski AR, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther, 2009, 330(3): 964-970.
[2]. Cheriyan J, Webb AJ, Sarov-Blat L, et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation., 2011, 123(5): 515-523.
[3]. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol, 2012, 52(3): 416-424.
- Confluentin
Catalog No.:BCN5795
CAS No.:585534-03-8
- Schisantherin A
Catalog No.:BCN1024
CAS No.:58546-56-8
- Schisantherin B
Catalog No.:BCN1023
CAS No.:58546-55-7
- Gomisin A
Catalog No.:BCN5794
CAS No.:58546-54-6
- Cucurbitacin IIA
Catalog No.:BCN5019
CAS No.:58546-34-2
- Rebaudioside B
Catalog No.:BCN2612
CAS No.:58543-17-2
- Rebaudioside A
Catalog No.:BCN5900
CAS No.:58543-16-1
- (-)-Cephaeline dihydrochloride
Catalog No.:BCN8323
CAS No.:5853-29-2
- Pseurotin A
Catalog No.:BCN7246
CAS No.:58523-30-1
- IOX 1
Catalog No.:BCC6192
CAS No.:5852-78-8
- ent-16beta,17-Isopropylidenedioxykaurane
Catalog No.:BCN1408
CAS No.:58493-71-3
- Olvanil
Catalog No.:BCC6855
CAS No.:58493-49-5
- Saikosaponin B1
Catalog No.:BCN5917
CAS No.:58558-08-0
- Saikosaponin B4
Catalog No.:BCN8516
CAS No.:58558-09-1
- Anagrelide HCl
Catalog No.:BCC2306
CAS No.:58579-51-4
- m-Anisic acid
Catalog No.:BCC9015
CAS No.:586-38-9
- H- ß-HoGlu-OH.HCl
Catalog No.:BCC3232
CAS No.:58610-41-6
- Boc-ON
Catalog No.:BCC2797
CAS No.:58632-95-4
- PH-797804
Catalog No.:BCC3672
CAS No.:586379-66-0
- Boc-Cys(Acm)-ONp
Catalog No.:BCC3375
CAS No.:58651-76-6
- 2-C-Methyl-D-erythritol
Catalog No.:BCC8570
CAS No.:58698-37-6
- 3,4-Dichloro-Phe-OH
Catalog No.:BCC2636
CAS No.:587-56-4
- Dihydrokavain
Catalog No.:BCN2677
CAS No.:587-63-3
- H-D-Cha-OH
Catalog No.:BCC2662
CAS No.:58717-02-5
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.[Pubmed:26273189]
Drug Des Devel Ther. 2015 Aug 5;9:4279-86.
Each year, despite optimal use of recommended acute and secondary prevention therapies, 4%-5% of patients with acute coronary syndrome (ACS) experience relapse of ACS or other cardiovascular events including stroke, heart failure, or sudden cardiac death after the index ACS. The sudden atherosclerotic plaque rupture leading to an ACS event is often accompanied by inflammation, which is thought to be a key pathogenic pathway to these excess cardiovascular events. Losmapimod is a novel, oral p38 mitogen-activated protein kinase (MAPK) inhibitor that targets MAPKs activated in macrophages, myocardium, and endothelial cells that occur as a part of global coronary vascular inflammation following plaque rupture. This review aims to 1) discuss the pathophysiological pathways through which p38 MAPKs may play key roles in initiation and progression of inflammatory disease and how Losmapimod is thought to counteract these p38 MAPKs, and 2) to describe the efficacy and safety data for Losmapimod obtained from preclinical studies and randomized controlled trials that support the hypothesis that it has promise as a treatment for patients with ACS.
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.[Pubmed:27043082]
JAMA. 2016 Apr 19;315(15):1591-9.
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor Losmapimod attenuates inflammation and may improve outcomes. OBJECTIVE: To evaluate the efficacy and safety of Losmapimod on cardiovascular outcomes in patients hospitalized with an acute myocardial infarction. DESIGN, SETTING, AND PATIENTS: LATITUDE-TIMI 60, a randomized, placebo-controlled, double-blind, parallel-group trial conducted at 322 sites in 34 countries from June 3, 2014, until December 8, 2015. Part A consisted of a leading cohort (n = 3503) to provide an initial assessment of safety and exploratory efficacy before considering progression to part B (approximately 22,000 patients). Patients were considered potentially eligible for enrollment if they had been hospitalized with an acute MI and had at least 1 additional predictor of cardiovascular risk. INTERVENTIONS: Patients were randomized to either twice-daily Losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline-recommended therapy. Patients were treated for 12 weeks and followed up for an additional 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization with the principal analysis specified at week 12. RESULTS: In part A, among the 3503 patients randomized (median age, 66 years; 1036 [29.6%] were women), 99.1% had complete ascertainment for the primary outcome. The primary end point occurred by 12 weeks in 123 patients treated with placebo (7.0%) and 139 patients treated with Losmapimod (8.1%; hazard ratio, 1.16; 95% CI, 0.91-1.47; P = .24). The on-treatment rates of serious adverse events were 16.0% with Losmapimod and 14.2% with placebo. CONCLUSIONS AND RELEVANCE: Among patients with acute MI, use of Losmapimod compared with placebo did not reduce the risk of major ischemic cardiovascular events. The results of this exploratory efficacy study did not justify proceeding to a larger efficacy trial in the existing patient population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02145468.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.[Pubmed:27136906]
Clin Pharmacol Drug Dev. 2015 Jul;4(4):262-9.
This phase 1 study characterized the safety, tolerability, pharmacokinetics, and pharmacodynamics of Losmapimod and its metabolite GSK198602 following single and repeat doses of oral Losmapimod in healthy Japanese volunteers. Subjects (n = 41) received single oral doses of Losmapimod (2.5, 7.5, 20 mg) or matching placebo on 3 separate days (n = 20) or Losmapimod 7.5 mg or matching placebo twice daily for 14 days (n = 21). Assessments included maximum observed plasma concentration (Cmax ), time to Cmax (Tmax ), apparent terminal-phase half-life (t1/ )2 , area under the curve (AUC), and change in C-reactive protein and phosphorylated heat shock protein 27 levels. No serious adverse events occurred during the study, and there were no safety concerns regarding clinical laboratory parameters, 12-lead electrocardiogram, or vital signs. The Losmapimod Tmax was 3-4 hours, and the mean t1/2 was approximately 7.9-9.0 hours, with no appreciable difference in Tmax and apparent clearance following oral dosing between dosing regimens. Single and repeat oral doses of Losmapimod were well tolerated in healthy Japanese volunteers. The Tmax of GSK198602 was similar to and t1/2 was slightly longer than those of Losmapimod. Approximate dose-proportional increases in exposure to Losmapimod and GSK198602 were observed in AUC with single-dose administration. Repeat-dose trough concentrations reached steady state within 2 days, with an observed accumulation ratio of 1.56 and 1.91 for Losmapimod and GSK198602, respectively.